Phillips-Medisize announced plans to open a new 80,000 square ft manufacturing facility on its Menomonie, Wis. campus. The state-of-the-art facility manufactures high volume prefilled drug delivery systems and is planned to be complete in 2017. Investment in the new facility is driven by the signing of a new supply contract with a major biopharmaceutical company and is expected to employ more than 100 people at full production.
The new facility allows for continued expansion. Business growth continues to accelerate as customers turn to Phillips-Medisize for complete design, development and manufacturing of combination products.
The expansion is the latest in a series over the last four years, reflecting continued growth of contract design, development and manufacturing capabilities to serve the drug delivery, consumable diagnostics and medical/surgical customers. Phillips-Medisize has also been dedicated to investing in its people through a strong collaboration with the University of Wisconsin-Stout, located in Menomonie, which provides technical resources and an educated work force prepared to meet the growing demand of the drug delivery industry.
This past summer Phillips-Medisize acquired Medicom Innovation Partner, in Denmark, who focuses on the design and development of connected health drug delivery systems and combination devices. Earlier in 2016, Phillips-Medisize opened a 17,000 square ft dedicated clinical and pilot build facility for drug delivery and combination devices in Menomonie, Wis.
Last November, the Company doubled the size of the New Richmond, Wis. medical device facility and in late 2014 expanded its Finland facility. These investments demonstrate ongoing support for biopharmaceutical customers by providing design, development and manufacturing solutions.